Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524404 | NSE Symbol : MARKSANS | ISIN : INE750C01026 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
11-Jul-2025	11-Jul-2025	AGM	The Board in its meeting approved the Annual General Meeting related Matters and fixed August 8, 2025 as the Annual General Meeting date.
08-May-2025	19-May-2025	Accounts	Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve 1. To consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31 2025. 2. To consider recommendation of dividend on the equity shares for the financial year 2024-25 if any. The Board in its meeting considered and approved of results for the year ended March 31 2025, recommendation of dividend and other related matters Recommended a final dividend of Rs. 0.80 per Equity Share (face value Re. 1 per share) for the financial year 2024-25. The dividend, if approved by the Members at the forthcoming Annual General Meeting ('AGM') will be credited / dispatched within 30 days from the date of AGM. (As Per BSE Announcement Dated on :19.05.2025)
22-Jan-2025	11-Feb-2025	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve unaudited financial results, standalone and consolidated, for the quarter and nine months ended December 31, 2024. Kindly find enclosed outcome of Board meeting for the quarter ended and nine months ended December 31, 2024 (As Per BSE Announcement Dated on 11.02.2025)
23-Oct-2024	12-Nov-2024	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone And Consolidated) For The Quarter and half year ended September 30 2024 PFA (As Per BSE Announcement Dated on 12.11.2024)
31-Jul-2024	13-Aug-2024	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the unaudited financial results (Standalone and Consolidated) for quarter ended June 30 2024 Kindly find enclosed the outcome of Board meeting. (As Per Bse Announcement Dated on 13.08.2024)
13-May-2024	30-May-2024	Final Dividend	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and year ended March 31 2024 and; Recommendation of dividend for FY2023-24 The Board has approved final dividend of Rs. 0.60 per equity share (As Per BSE Announcement dated on 30.05.2024)
17-Jan-2024	13-Feb-2024	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the unaudited financial results (Standalone and Consolidated) for the quarter and nine months ended December 31 2023 Quarterly financial results for quarter ended December 31, 2023 (As per BSE Announcement Dated on 13/02/2024)
27-Oct-2023	09-Nov-2023	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve To consider and approve the unaudited financial results of the Company (both standalone and consolidated) for the quarter and half year ended September 30 2023 Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and other regulations, if applicable, we hereby inform the Exchanges that the Board of Directors ('Board') of the Company at its Meeting held on November 09, 2023 has, inter alia, approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2023. The meeting commenced at 12:00 p.m. and concluded at 12:50 p.m. (As per BSE Announcement Dated on 09/11/2023)
02-Aug-2023	11-Aug-2023	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) along with Limited Review Report thereon for the Quarter ended 30th June 2023 Unaudited Consolidated and standalone financial results along with limited review reports for quarter ended June 30, 2023 (As Per BSE Announcement Dated on 11.08.2023)
17-May-2023	30-May-2023	Accounts	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended 31st March 2023. The Board of Directors will also consider recommendation of dividend if any for the Financial Year 2022-23. Outcome of Board Meeting (As per BSE Announcement Dated on 30/05/2023)
03-Feb-2023	13-Feb-2023	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Nine Months ended 31st December 2022. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and nine months ended 31st December, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th February, 2023 along with Limited Review Reports given by statutory auditor of the Company. (As Per BSE Announcement Dated on 13/02/2023)
11-Jan-2023	20-Jan-2023	Conversion	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2023 inter alia to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis. This is to inform you that the Board of Directors at its meeting held today, i.e., 20th January, 2023, has created, issued and allotted fully paid-up Equity Shares having face value of Re. 1/- each on conversion of convertible warrants issued on preferential basis. (As Per BSE Announcement dated on 20.01.2023)
02-Nov-2022	14-Nov-2022	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve the unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and half-year ended 30th September 2022. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended 30th September, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 14th November, 2022 along with Limited Review Reports given by statutory auditor of the Company. The meeting commenced at 06:45 p.m. and concluded at 07:45 p.m. (As Per BSE Announcement Dated on 14/11/2022) This is to inform you that based on the recommendation of Audit Committee, the Board of Directors of the Company at its Meeting held on 14thNovember, 2022 has approved the appointment of M/s. JVJ & Co., Chartered Accountants firm (Firm Registration No: 141427W) as the Internal Auditor of the Company, in accordance with the provision of Section 138 of the Companies Act, 2013 read with rules made thereto. The details as required under Regulation 30SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as Annexure-I. (As per BSE Announcement Dated on 15/11/2022)
01-Aug-2022	13-Aug-2022	Quarterly Results	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter ended 30th June 2022. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th August, 2022 along with Limited Review Reports given by statutory auditor of the Company. The meeting commenced at 6:20 p.m. and concluded at 7:40 p.m. (As Per BSE Announcement Dated on 13/08/2022)
04-Jul-2022	08-Jul-2022	Buy Back	MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/07/2022 inter alia to consider and approve the proposal for buyback of fully paid up equity shares of the Company upto such amount of the aggregate of Companys paid up equity share capital and free reserves as the Board may decide in accordance with the provisions of Section 68 69 and 70 of the Companies Act 2013 and the SEBI (Buyback of Securities) Regulations 2018. It is further submitted that in terms of the Companys Code of Conduct to Regulate Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended the trading window for dealing in the shares of the Company for the designated person(s) is already closed w.e.f. July 01 2022 and will remain closed till 48 hours after the declaration of unaudited financial results for the quarter ended June 30 2022. Board approved the proposal to Buyback its own fully paid up Equity Shares of face value Re. 1/- each upto a maximum price of Rs. 60.00 (Indian Rupees Sixty only) per Equity Share ('Maximum Buyback Price') payable in cash for an aggregate Buyback consideration not exceeding Rs. 6000.00 Lakhs (Indian Rupees Six Thousand Lakhs only) ('Maximum Offer Size') which is 8.78% and 5.79% of the paid up share capital, free reserves and securities premium of the Company as per the latest audited standalone and consolidated financial statements of the Company, respectively, for the financial year ended March 31, 2022 through the Open Market route on the Stock Exchanges Le., National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') (NSE and BSE are collectively referred to as the 'Stock Exchanges'), as prescribed under the SEBI (Buyback of Securities) Regulations, 2018 ('SEBI Buyback Regulations') and the Act (the process being referred herein as 'Buyback') from the equity shareholders / beneficial owners of the Equity Shares of the Company (other than those who are promoters, members of the promoter group and persons in control of the Company). The Maximum Buyback Size shall not include any expenses incurred or to be incurred for the Buyback like filing fees payable to the SEBI, merchant banker fees, stock exchange fee, transaction costs viz. brokerage, applicable taxes inter- alia including tax on distributed income to hareholders, Securities Transaction Tax, Goods and Services Tax, Stamp duty, etc., public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses. Subject to the market price of the Equity Share being equal to or less than the Maximum Buyback Price, the indicative maximum number of Equity Shares bought back would be 1,00,00,000 (One Crore) Equity Shares ('Indicative Maximum Buyback Shares'), comprising approximately 2.44% of the paid up Equity Share capital of the Company as of March 31, 2022. If the Equity Shares are bought back at a price below the Maximum Buyback Price, the actual number of Equity Shares bought back could exceed the Indicative Maximum Buyback Shares, but will always be subject to the Maximum Buyback Sizeand will not be exceed 25% of the paid-up Equity Share capital of the Company as at March 31, 2022. The Company shall utilise at least 50% of the amount earmarked as the Maximum Buyback Size for the Buyback Le., Rs. 3000.00 Lakhs (Indian Rupees Three Thousand Lakhonly) ('Minimum Buyback Size'). Based on the Minimum Buyback Size and Maximum Buyback Price, the Company would purchase a minimum of 50,00,000 (Fifty Lakh) Equity Shares('Minimum Buyback Shares'). The Board also noted the Buyback being proposed to be undertaken through Stock Exchange route, the Promoter and Promoter Group and persons in control of the Company will not participate in the Buyback. (As Per BSE Bulletin Dated on 08.07.2022) In furtherance to the outcome letter dated July 08, 2022, and pursuant to the Regulation 5(vii) of the SEBI (Buy-back of Securities) Regulations, 2018, enclosed herewith is the certified true copy of the resolution passed by the board of directors at its meeting held on July 08, 2022, approving the buyback of equity shares of the Company. (As Per BSE Announcement dated on 12.07.2022)

1 2

LOGIN HERE

Marksans Pharma Ltd

Board Meeting